SRC and pancreatic neoplasm: WTAP can activate the Fak-Src-GRB2-Erk1/2 and Fak-PI3K-AKT signaling pathways to restrain the chemosensitivity of pancreatic cancer cells to gemcitabine, and Fak inhibitors have been shown to be able to rescue high WTAP-mediated chemo-tolerance to gemcitabine in pancreatic cancer [56].